FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma By Ogkologos - July 18, 2025 443 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally... November 3, 2020 Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma November 29, 2022 FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease August 17, 2021 Choosing to act on cancer: Our Manifesto for Cancer Research and... April 20, 2023 Load more HOT NEWS Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate... FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term...
